+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncology Drugs Market - Global Forecast 2026-2032- Product Image
Oncology Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Oncology Drugs Market - Global Forecast 2026-2032

  • Report

  • 180 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896719
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oncology Drugs Market is projected to reach USD 242.32 Billion in 2026. It is expected to continue growing at a CAGR of 7.55%, reaching USD 376.10 Billion by 2032.

The oncology drugs market is being reshaped by rising cancer incidence, precision medicine, and the rapid expansion of immuno-oncology, targeted therapy, antibody-drug conjugates, radiopharmaceuticals, and cell and gene therapies. According to the International Agency for Research on Cancer’s GLOBOCAN 2022 estimates, there were approximately 20 million new cancer cases and 9.7 million cancer deaths worldwide, underscoring the sustained clinical need for effective cancer therapeutics.

Demand is increasingly concentrated around therapies that improve survival, reduce toxicity, and align treatment with molecular diagnostics. Regulatory approvals from the U.S. Food and Drug Administration and the European Medicines Agency show continued momentum for biomarker-directed indications, tumor-agnostic therapies, and expedited pathways for serious cancers with unmet need. For industry leaders, competitive advantage now depends on evidence generation, companion diagnostics, access strategy, manufacturing resilience, and lifecycle management across global oncology care settings.

Transformative Shifts in the Oncology Drugs Landscape

The oncology therapeutics landscape is moving from broad cytotoxic regimens toward more personalized, combination-based treatment models. Immune checkpoint inhibitors, kinase inhibitors, PARP inhibitors, bispecific antibodies, CAR-T cell therapies, antibody-drug conjugates, and radioligand therapies are expanding treatment options across hematologic malignancies and solid tumors.

A major transformative shift is the integration of diagnostics into drug development and clinical decision-making. Biomarkers such as PD-L1, MSI-H/dMMR, EGFR, ALK, HER2, BRCA, BRAF, NTRK, and KRAS G12C increasingly determine eligibility, sequencing, and expected response. At the same time, payers and health systems are demanding real-world evidence, comparative effectiveness data, patient-reported outcomes, and outcomes-based value narratives as oncology drug costs rise and treatment pathways become more complex.

Cumulative Impact of Artificial Intelligence in Oncology Drugs

Artificial intelligence is having a cumulative impact across oncology drug discovery, clinical development, medical affairs, and commercialization. AI-enabled models are used to analyze genomics, pathology images, radiology scans, electronic health records, and clinical trial datasets to identify targets, stratify patients, predict response, and improve trial feasibility.

The strongest near-term value is emerging in patient matching, adaptive trial design, pharmacovigilance signal detection, biomarker discovery, synthetic control arm development, and evidence synthesis from real-world datasets. However, adoption depends on validated datasets, transparent model governance, regulatory alignment, cybersecurity safeguards, bias mitigation, and clinical usability. In oncology, where treatment decisions can be life-critical, AI must augment expert judgment rather than replace evidence-based medical practice.

Key Regional Insights Across Oncology Drug Markets

North America remains a central hub for oncology drug innovation, supported by advanced clinical trial infrastructure, high biomarker testing adoption, substantial biomedical research investment, and U.S. regulatory programs that support expedited development for serious diseases. The United States anchors regional demand through broad availability of novel immunotherapies, targeted therapies, and advanced cellular therapies, while Canada emphasizes health technology assessment, pan-Canadian review processes, and provincial reimbursement pathways that shape access timelines.

Europe combines strong scientific capabilities with a structured regulatory and reimbursement environment shaped by the European Medicines Agency, national health technology assessment bodies, and cross-border cancer policy initiatives. The region’s oncology drug landscape is influenced by centralized medicine evaluation, national pricing negotiations, and growing emphasis on equitable cancer care under European cancer policy frameworks. Asia-Pacific is gaining importance through China’s expanding biopharmaceutical sector, Japan’s mature oncology treatment environment, South Korea’s clinical research ecosystem, India’s high patient volumes and biosimilar capabilities, and Australia’s advanced regulatory and trial capabilities.

Latin America presents meaningful unmet need, with Brazil and Mexico serving as key access and commercialization markets, although reimbursement variability, out-of-pocket burden, and diagnostic infrastructure gaps remain important constraints. The Middle East is increasing investment in oncology centers, genomic medicine, and specialty care, particularly in Gulf countries where national health transformation programs are strengthening cancer services. Africa faces the largest access challenges, including late diagnosis, limited oncology workforce, constrained pathology and radiotherapy capacity, and restricted availability of advanced therapies, making affordability, early detection, and essential cancer medicines critical priorities.

Key Group Insights for Oncology Drug Strategy

Within ASEAN, oncology drug demand is increasing as cancer screening, specialty hospitals, pathology capacity, and national reimbursement schemes expand, but access remains uneven across high-income and lower-middle-income member states. Countries with stronger universal health coverage and tertiary cancer networks are better positioned to adopt biomarker-driven therapies, while others continue to prioritize essential cancer medicines, diagnostic scale-up, and affordability. The GCC is investing in cancer centers, genomic testing, specialty hospital networks, and national cancer strategies, creating demand for innovative oncology drugs while emphasizing procurement efficiency, local health system priorities, and workforce development.

The European Union remains influential through centralized medicine evaluation, pharmacovigilance standards, joint clinical assessment under evolving health technology assessment rules, and policy initiatives tied to Europe’s Beating Cancer Plan. These mechanisms are reinforcing evidence expectations for oncology drugs, including comparative clinical benefit, quality-of-life outcomes, and real-world effectiveness. BRICS markets are strategically important because they combine large patient populations, growing domestic manufacturing capacity, expanding biosimilar use, and increasing participation in global oncology trials, although affordability, regional access variation, and reimbursement complexity differ widely across member countries.

G7 countries remain the most commercially significant group for premium oncology innovation due to mature reimbursement systems, strong academic oncology networks, advanced clinical trial infrastructure, and high adoption of biomarker-driven care. NATO countries overlap heavily with advanced North American and European markets, where medicine security, resilient supply chains, cybersecurity, and protection of critical health infrastructure are becoming increasingly relevant to oncology drug availability, especially for biologics, radiopharmaceuticals, and complex personalized therapies.

Key Country Insights in Oncology Drugs

The United States leads global oncology commercialization through high clinical trial activity, frequent oncology regulatory approvals, academic cancer centers, advanced molecular testing, and broad use of immunotherapy, targeted therapy, and cellular therapy in eligible populations. Canada prioritizes evidence-based reimbursement through national and provincial review structures, while Mexico and Brazil represent major Latin American opportunities shaped by public-sector access, private insurance coverage, expanding oncology networks, and persistent disparities in timely diagnosis and biomarker testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine strong oncology expertise with national reimbursement assessment and established specialist care pathways, while Germany’s early access and benefit assessment pathway remains especially important for launch planning. The United Kingdom continues to emphasize health technology assessment and managed access mechanisms, France applies structured clinical benefit evaluation, and Italy and Spain balance national assessment with regional implementation. Russia remains a complex oncology market influenced by localization requirements, procurement structures, regulatory considerations, and geopolitical constraints that affect access and supply continuity.

China has become a major force in oncology research and development, clinical trials, and domestic biologics innovation, supported by regulatory reforms, expanding hospital capacity, and rising use of targeted therapies and immuno-oncology in specialist centers. India offers large patient volumes, deep generic and biosimilar manufacturing capabilities, and growing oncology service capacity, though affordability and uneven diagnostic access remain central. Japan maintains strong uptake of innovative oncology drugs under a mature regulatory and reimbursement system, South Korea is a leading clinical research and biopharma innovation hub with advanced hospital networks, and Australia supports high-quality trials, genomic medicine initiatives, and early adoption through robust regulatory oversight.

Actionable Recommendations for Oncology Industry Leaders

Industry leaders should prioritize biomarker-driven development plans that connect clinical trial design, companion diagnostics, regulatory submissions, and market access evidence from the earliest stages. Oncology drug portfolios should be evaluated not only by tumor type but also by mechanism of action, resistance biology, sequencing potential, tolerability, combination strategy, and ability to address clearly defined unmet need.

Organizations should strengthen real-world evidence capabilities, diversify clinical trial recruitment, and build access models that address affordability across mature and emerging markets. Supply chain resilience is essential for biologics, radiopharmaceuticals, and cell therapies, where cold chain reliability, isotope availability, manufacturing slots, quality systems, and site certification can directly affect patient access. Leaders should also align medical education, diagnostic partnerships, and value communication to ensure that eligible patients can be identified and treated appropriately.

Research Methodology for Oncology Drug Market Analysis

This executive summary is built on secondary research from validated public sources, including the World Health Organization, the International Agency for Research on Cancer’s GLOBOCAN database, the U.S. Food and Drug Administration, the European Medicines Agency, national cancer agencies, peer-reviewed oncology literature, clinical trial registries, treatment guidelines, and public regulatory documents. The analysis evaluates disease burden, regulatory trends, therapeutic innovation, regional access dynamics, diagnostic readiness, and healthcare infrastructure indicators.

Insights were synthesized using a structured market intelligence framework that compares clinical evidence, treatment pathways, approval activity, reimbursement considerations, biomarker adoption, manufacturing requirements, and geographic adoption patterns. Emphasis was placed on verifiable information and directional conclusions supported by recognized oncology data sources rather than speculative projections, market sizing, or forecasting.

Conclusion: Strategic Outlook for Oncology Drugs

The oncology drugs market is entering a more precise, data-intensive, and access-sensitive phase. Scientific progress is expanding treatment options across immunotherapy, targeted therapy, antibody-drug conjugates, radiopharmaceuticals, and cell-based therapies, but success increasingly depends on proving differentiated clinical value, enabling diagnostics, and ensuring timely availability across diverse healthcare systems.

Organizations that combine strong research productivity with biomarker strategy, AI-enabled evidence generation, regulatory discipline, manufacturing reliability, and equitable access planning will be best positioned to lead in the next phase of oncology therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oncology Drugs Market, by Drug Class
7.1. Introduction
7.2. Chemotherapy Agents
7.2.1. Alkylating Agents
7.2.2. Antimetabolites
7.3. Hormonal Therapy Agents
7.4. Immunotherapy Agents
7.4.1. CAR T-Cell Therapy
7.4.2. Checkpoint Inhibitors
7.4.2.1. CTLA-4 Inhibitors
7.4.2.2. PD-1/PD-L1 Inhibitors
7.5. Targeted Therapy Agents
7.5.1. Monoclonal Antibodies
7.5.1.1. Chimeric
7.5.1.2. Humanized
7.5.2. Small Molecule Inhibitors
7.5.2.1. Cyclin-Dependent Kinase Inhibitors
7.5.2.2. Tyrosine Kinase Inhibitors
8. Oncology Drugs Market, by Route of Administration
8.1. Introduction
8.2. Injectable
8.2.1. Intramuscular
8.2.2. Intravenous
8.2.3. Subcutaneous
8.3. Oral
9. Oncology Drugs Market, by Molecule Type
9.1. Introduction
9.2. Biologics
9.2.1. Monoclonal Antibodies
9.2.2. Vaccines
9.3. Small Molecules
10. Oncology Drugs Market, by Indication
10.1. Introduction
10.2. Blood Cancer
10.2.1. Leukemia
10.2.1.1. Acute Myeloid Leukemia
10.2.1.2. Chronic Lymphocytic Leukemia
10.2.2. Lymphoma
10.2.2.1. Hodgkin Lymphoma
10.2.2.2. Non-Hodgkin Lymphoma
10.3. Breast Cancer
10.4. Colorectal Cancer
10.5. Lung Cancer
10.6. Prostate Cancer
11. Oncology Drugs Market, by End User
11.1. Introduction
11.2. Hospitals
11.3. Research Institutes
11.4. Specialty Clinics
12. Oncology Drugs Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Oncology Drugs Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Oncology Drugs Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Oncology Drugs Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Ltd.
17.2. AbbVie Inc.
17.3. Agenus Inc.
17.4. Amgen Inc.
17.5. Après-demain SA
17.6. Aspen Pharmacare Holdings Limited
17.7. Astellas Pharma Inc.
17.8. AstraZeneca PLC
17.9. Bayer AG
17.10. BeiGene, Inc.
17.11. Biovista Inc.
17.12. Blueprint Medicines Corporation
17.13. Bristol-Myers Squibb Company
17.14. C.H. Boehringer Sohn AG & Co. KG
17.15. Cellectar Biosciences, Inc.
17.16. Cipla Limited
17.17. Dr Reddy's Laboratories Ltd.
17.18. Eisai Co., Ltd.
17.19. Eli Lilly and Company
17.20. Exelixis, Inc.
17.21. F. Hofmann-La Roche Ltd.
17.22. Genentech, Inc
17.23. GlaxoSmithKline PLC
17.24. Glenmark Pharmaceuticals Ltd.
17.25. Hetero Healthcare Limited
17.26. Ipsen SA
17.27. Janssen Pharmaceuticals, Inc.
17.28. Johnson & Johnson Services, Inc.
17.29. Lupin Limited
17.30. Merck & Co., Inc.
17.31. Merck KGaA
17.32. MSN Laboratories
17.33. Natco Pharma Ltd.
17.34. Novartis AG
17.35. Pfizer Inc.
17.36. Puma Biotechnology, Inc.
17.37. Sanofi S.A.
17.38. Sun Pharmaceutical Industries Ltd
17.39. Sutro Biopharma, Inc.
17.40. Takeda Pharmaceutical Company Limited
17.41. Teva Pharmaceutical Industries Ltd
17.42. Vascular Biogenics Ltd.
17.43. Viatris Inc.
List of Figures
FIGURE 1. GLOBAL ONCOLOGY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ONCOLOGY DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ONCOLOGY DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ONCOLOGY DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL ONCOLOGY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL ONCOLOGY DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ONCOLOGY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ONCOLOGY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CHEMOTHERAPY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ALKYLATING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL ANTIMETABOLITES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL ANTIMETABOLITES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL ANTIMETABOLITES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL HORMONAL THERAPY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL HORMONAL THERAPY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL HORMONAL THERAPY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL IMMUNOTHERAPY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL IMMUNOTHERAPY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL IMMUNOTHERAPY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CHECKPOINT INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL CTLA-4 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PD-1/PD-L1 INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PD-1/PD-L1 INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PD-1/PD-L1 INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL TARGETED THERAPY AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL TARGETED THERAPY AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TARGETED THERAPY AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CHIMERIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CHIMERIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL CHIMERIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL HUMANIZED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL HUMANIZED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL HUMANIZED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SMALL MOLECULE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL CYCLIN-DEPENDENT KINASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL CYCLIN-DEPENDENT KINASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL CYCLIN-DEPENDENT KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL TYROSINE KINASE INHIBITORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL BLOOD CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL BLOOD CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL BLOOD CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ACUTE MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL NON-HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 138. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 139. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 140. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 141. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 142. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 143. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 144. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 145. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 146. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 154. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 155. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 156. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 157. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 158. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 159. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 160. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 161. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 162. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 163. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 164. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 165. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 166. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 167. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 168. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 169. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 170. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 171. EUROPE ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 173. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 174. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 175. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 176. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 177. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 178. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 179. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 180. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 181. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 182. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 183. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 184. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 185. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 186. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 192. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 193. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 194. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 195. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 196. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 197. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 198. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 199. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 200. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 201. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 202. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 203. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 204. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 208. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 209. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 210. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 211. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 212. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 213. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 214. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 215. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 216. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 217. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 218. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 219. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 220. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 221. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 222. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 223. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 224. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 225. AFRICA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 226. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 227. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 228. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 229. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 230. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 231. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 232. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 233. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 234. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 235. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 236. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 237. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 238. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 239. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 240. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 241. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 242. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. MIDDLE EAST ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 244. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 245. NATO ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 246. NATO ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 247. NATO ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 248. NATO ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 249. NATO ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 250. NATO ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 251. NATO ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 252. NATO ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 253. NATO ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 254. NATO ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 255. NATO ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 256. NATO ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 257. NATO ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 258. NATO ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 259. NATO ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 260. NATO ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 261. NATO ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 262. NATO ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 263. G7 ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 264. G7 ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 265. G7 ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 266. G7 ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 267. G7 ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 268. G7 ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 269. G7 ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 270. G7 ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 271. G7 ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 272. G7 ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 273. G7 ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 274. G7 ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 275. G7 ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 276. G7 ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 277. G7 ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 278. G7 ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 279. G7 ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 280. G7 ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 281. BRICS ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 282. BRICS ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 283. BRICS ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 284. BRICS ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 285. BRICS ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 286. BRICS ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 287. BRICS ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 288. BRICS ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 289. BRICS ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 290. BRICS ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 291. BRICS ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 292. BRICS ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 293. BRICS ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 294. BRICS ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 295. BRICS ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 296. BRICS ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 297. BRICS ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 298. BRICS ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 299. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 300. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 301. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 302. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 303. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 304. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 305. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 306. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 307. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 308. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 309. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 310. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 311. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 312. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 313. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 314. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 315. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 316. EUROPEAN UNION ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 317. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 318. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 319. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 320. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 321. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 322. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 323. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 324. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 325. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 326. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 327. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 328. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 329. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 330. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 331. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 332. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 333. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. ASEAN ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 335. GCC ONCOLOGY DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 336. GCC ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 337. GCC ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 338. GCC ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 339. GCC ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 340. GCC ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 341. GCC ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 342. GCC ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 343. GCC ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 344. GCC ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 345. GCC ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 346. GCC ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 347. GCC ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 348. GCC ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 349. GCC ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 350. GCC ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 351. GCC ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 352. GCC ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 353. GLOBAL ONCOLOGY DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 354. CHINA ONCOLOGY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 355. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 356. CHINA ONCOLOGY DRUGS MARKET SIZE, BY CHEMOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 357. CHINA ONCOLOGY DRUGS MARKET SIZE, BY IMMUNOTHERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 358. CHINA ONCOLOGY DRUGS MARKET SIZE, BY CHECKPOINT INHIBITORS, 2017-2032 (USD MILLION)
TABLE 359. CHINA ONCOLOGY DRUGS MARKET SIZE, BY TARGETED THERAPY AGENTS, 2017-2032 (USD MILLION)
TABLE 360. CHINA ONCOLOGY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 361. CHINA ONCOLOGY DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2017-2032 (USD MILLION)
TABLE 362. CHINA ONCOLOGY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 363. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INJECTABLE, 2017-2032 (USD MILLION)
TABLE 364. CHINA ONCOLOGY DRUGS MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 365. CHINA ONCOLOGY DRUGS MARKET SIZE, BY BIOLOGICS, 2017-2032 (USD MILLION)
TABLE 366. CHINA ONCOLOGY DRUGS MARKET SIZE, BY INDICATION, 2017-2032 (USD MILLION)
TABLE 367. CHINA ONCOLOGY DRUGS MARKET SIZE, BY BLOOD CANCER, 2017-2032 (USD MILLION)
TABLE 368. CHINA ONCOLOGY DRUGS MARKET SIZE, BY LEUKEMIA, 2017-2032 (USD MILLION)
TABLE 369. CHINA ONCOLOGY DRUGS MARKET SIZE, BY LYMPHOMA, 2017-2032 (USD MILLION)
TABLE 370. CHINA ONCOLOGY DRUGS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 371. CHINA ONCOLOGY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 372. UNITED STATES ONCOLOGY DRUGS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 373.

Companies Mentioned

  • Abbott Ltd.
  • AbbVie Inc.
  • Agenus Inc.
  • Amgen Inc.
  • Après-demain SA
  • Aspen Pharmacare Holdings Limited
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Inc.
  • Biovista Inc.
  • Blueprint Medicines Corporation
  • Bristol-Myers Squibb Company
  • C.H. Boehringer Sohn AG & Co. KG
  • Cellectar Biosciences, Inc.
  • Cipla Limited
  • Dr Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Exelixis, Inc.
  • F. Hofmann-La Roche Ltd.
  • Genentech, Inc
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Healthcare Limited
  • Ipsen SA
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Merck KGaA
  • MSN Laboratories
  • Natco Pharma Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Puma Biotechnology, Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Vascular Biogenics Ltd.
  • Viatris Inc.

Table Information

Report AttributeDetails
No. of Pages180
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 242.32 Billion
Forecasted Market Value ( USD ) by 2032 $ 376.1 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal
No. of Companies Mentioned43

Related Topics

Related Reports

Generic Oncology Drugs Market - Global Forecast 2026-2032 - Product Image

Generic Oncology Drugs Market - Global Forecast 2026-2032

  • Report
  • 193 Pages
  • Global
From
Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032 - Product Image

Cancer Immunotherapy Drugs Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 246 Pages
  • Global
From
Bispecific Antibodies - Global Strategic Business Report - Product Image

Bispecific Antibodies - Global Strategic Business Report

  • Report
  • 104 Pages
  • Global
From
Immunotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034 - Product Image

Immunotherapy Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034

  • Drug Pipelines
  • 150 Pages
  • Global
From

About the Oncology Drugs Market

The Chemotherapy Agent market within the Healthcare Services sector is a rapidly growing industry. It is composed of a variety of products and services that are used to treat cancer and other diseases. These products and services include drugs, medical devices, and other treatments. The market is driven by the increasing prevalence of cancer and other diseases, as well as the development of new treatments and technologies. The Chemotherapy Agent market is highly competitive, with many companies offering a wide range of products and services. Companies in the market include Pfizer, Novartis, Merck, Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Roche. These companies are constantly innovating and developing new products and services to meet the needs of patients and healthcare providers. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.